Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review

Acasti Pharma Inc. (NASDAQ: ACST) is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population.

On August 14, 2018, the company’s shares were trading at $.45 per share. Since then the ACST shares have hit a high of $1.80 before settling at today’s level of $1.19.


On October 4th, 2018, the company announced that, in connection with its overnight marketed public offering previously announced on October 3, 2018, it has entered into an underwriting agreement with Mackie Research Capital Corporation to sell 18,750,000 Class A Shares at a price of C$1.28 per Common Share, for aggregate gross proceeds to Acasti of C$24,000,000.


On October 4, 2018, the Company also priced a separate and concurrent underwritten public offering of Common Shares in the United States (the “U.S. Offering”) at a price of US$1.00 for total gross proceeds of US$16,600,000.


Acasti’s TRILOGY Phase 3 clinical studies for its product candidate CaPre® (omega-3 phospholipid) are currently underway and will be conducted at approximately 140 sites across North America and as per management, the net proceeds received by the Company from the Offering, together with cash on hand and the U.S. Offering, are intended to be used by the Company for the further development of CaPre and to complete the Company’s Phase 3 program through to top-line results, including completion of clinical site activation, patient enrolment and randomization, and production of clinical materials (both CaPre and placebo) for the Company’s Phase 3 program; planning and initiation of the Company’s regulatory (NDA) submission; expansion of business development activities; working capital; and other general corporate purposes.


Before that on August 14th, the company announced its operating and financial results for the first quarter ending June 30, 2018. The company confirmed that its two TRILOGY Phase 3 studies remain on track to complete enrollment this year. Importantly, as of August 10, 2018 ACST reached almost 60% enrollment, with 770 patients enrolled, and 110 patients randomized at 126 clinical sites across the U.S., Canada, and Mexico. ACST continue to project that it will complete these studies on schedule in mid-2019 and expect to report top-line results before the end of 2019.


CaPre Development Timeline and Key Milestones:


Analysts tracking the stock believes that the addressable market for the company may expand significantly if omega-3s demonstrate long-term cardiovascular benefits in on-going outcomes studies (REDUCE-IT and STRENGTH). Acasti might need to conduct at least one additional clinical trial to support FDA approval of a supplemental New Drug Application to expand CaPre’s indications to this segment. With the upcoming milestones in its pipeline, a strengthened cash position, and expected development and distribution partnerships to market CaPre in major countries, Acasti is well poised for substantial growth for the foreseeable future.


As per, average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 422.39%. The high price target for ACST is $7.00, and the low-price target for ACST is $7.00. There are currently two buy ratings for the stock, resulting in a consensus rating of “Buy.”


Our members have booked up to 800% on our recent NASDAQ and NYSE small cap alerts. We will be initiating coverage on another exciting small cap security on 10/11/18 just after market open. View our recent picks, track record and sign up for our mobile/text alerts in real time here-


Below are the excerpts of recent analyst rating/Price targets on the company:



About the company:

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. The company is developing CaPre in Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. The company was incorporated in 2002 and is headquartered in Laval, Canada.


About Trilogy: TRILOGY, an acronym derived from “Phase 3 Studies of CaPre in Lowering Very High Triglycerides,” is a double-blind, placebo-controlled, 26-week, two-trial Phase 3 clinical program designed to evaluate the safety and efficacy of CaPre in patients with severe hypertriglyceridemia. TRILOGY 1 and TRILOGY 2 is running in parallel and will randomize a total of approximately 500 patients. The program is being conducted at approximately 150 sites across the U.S., Canada, and Mexico.


Key and Unique differentiating factor of the company:


First Quarter 2019 Financial Results:

ACST has a fiscal year end of March 31st.

  • Net loss for the first quarter ended June 30, 2018, was $7.4 million or $0.23 per share, compared to a net loss of $2.8 million or $0.19 per share for the quarter ended June 30, 2017. The higher net loss was primarily due to the planned increase in research and development expenses (“R&D”) for the TRILOGY Phase 3 program.
  • Cash flows – Cash and cash equivalents totaled $12.9 million as of June 30, 2018 and increased with $11.5 million in gross proceeds from the May 2018 underwritten public offering in Canada with the full exercise of the overallotment option. As previously disclosed, there exists a material uncertainty about the company’s ability to continue as a going concern and to realize its assets and discharge its liabilities in the normal course of business. Management has a reasonable expectation that the company should be able to raise additional funds later in 2018 to continue to finance the TRILOGY Phase 3 program for CaPre.


Key risk factors and potential stock drivers:

  • Any adversities related to the future guidance might adversely impact the overall investor sentiments.
  • Any time/cost overruns and or suspensions or delays in the completion of clinical testing could result in increased costs and delay or prevent its or certain of its subsidiaries’ ability to complete development of that product or generate product revenues.
  • Extensive industry regulation has had and will continue to have, an impact on ACST’ business in the area of cost of goods, especially its product development, manufacturing, and distribution capabilities.


Stock Chart:




  • On Tuesday, October 9th, 2018, ACST was at $1.19, on traded volume of 628K shares exchanging hands. Market capitalization is $87.772 million. The current RSI is at 59.62
  • In the past 52 weeks, shares of ACST shave traded as low as $0.43 and as high as $3.36
  • At $1.19, shares of ACST are trading above its 50-day moving average (MA) at $0.69 and above its 200-day moving average (MA) at $0.82
  • The present support and resistance levels for the stock are at $1.15 & $1.35 respectively.



Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.